Company profile
Kymab company profile
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.
Business identity
- Website
- http://www.kymab.com
- Contact email
- [email protected]
- Phone number
- 44 1223 833301
- Operating status
- Closed
- Company type
- For Profit
- Employee range
- 101-250 employees
- Revenue range
- $1M-$10M
- Founded
- 2010-01-01, Year
Headquarters
- Headquarters
- Cambridge, England, United Kingdom
- Postal code
- CB22 3AT
- Country code
- GB
- Continent
- Europe